Search Results for "Rayos"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Rayos. Results 1 to 4 of 4 total matches.
See also: prednisone
Delayed-Release Prednisone (Rayos)
The Medical Letter on Drugs and Therapeutics • Nov 26, 2012 (Issue 1404)
Delayed-Release Prednisone (Rayos) ...
The FDA has approved a delayed-release oral formulation
of prednisone (Rayos – Horizon Pharma). Rayos is
not labeled for any specific indication, but the only
published studies of the new product have been in
patients with rheumatoid arthritis (RA).
Ozanimod (Zeposia) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Sep 20, 2021 (Issue 1633)
delayed-release – Rayos (Horizon) 1, 2, 5 mg DR tabs4 Induction: 5 mg PO once/day 2762.10
Budesonide ...
The oral sphingosine 1-phosphate (S1P) receptor
modulator ozanimod (Zeposia – Bristol Myers Squibb)
has been approved by the FDA for treatment of adults
with moderately to severely active ulcerative colitis. It
is the first S1P receptor modulator to be approved for
treatment of ulcerative colitis. Ozanimod was approved
in March 2020 for use in adults with relapsing forms of
multiple sclerosis.
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
Rayos (Horizon)
1, 2.5, 5, 10, 20, 50 mg
tabs; 5 mg/5 mL, 5 mg/1
mL oral solution
1, 2, 5 mg DR ...
View the Table: Some Drugs for Inflammatory Bowel Disease
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e115-9 doi:10.58347/tml.2023.1680d | Show Introduction Hide Introduction
Drugs for Inflammatory Bowel Disease
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
: 40-60 mg PO once/day $18.30
5 mg/5 mL, 5 mg/1 mL oral solution
delayed-release
Rayos (Horizon) 1 ...
Ulcerative colitis (UC) and Crohn's disease (CD),
referred to collectively as inflammatory bowel disease
(IBD), are chronic immune-mediated inflammatory
conditions. Guidelines for treatment of UC and CD
have been updated in recent years
Med Lett Drugs Ther. 2023 Jul 10;65(1680):105-12 doi:10.58347/tml.2023.1680a | Show Introduction Hide Introduction